OBJECTIVE: The neuropeptide Y (NPY) Y5 receptor is presumed to be involved in the regulation of food intake. DESIGN: To investigate the possible role of this receptor in weight regulation, the whole coding region of the NPY Y5 receptor gene was screened for mutations using temperature gradient gel electrophoresis (TGGE). Detected mutations were screened in extended cohorts. STUDY COHORTS AND METHODS: Cohorts of 87 extremely obese children and adolescents, 15 underweight subjects and 25 patients with anorexia nervosa (AN) were initially screened by TGGE. Extended samples of these cohorts (160 obese children and adolescents; mean body mass index (BMI) 33.5 AE 6.4 kgam 2 , 128 underweight subjects; mean BMI 18.4 AE 1.0 kgam 2 and 58 patients with AN; mean BMI 14.6 AE 1.7 kgam 2 ) were screened to determine the frequencies of a detected mutation and a detected polymorphism in the NPY Y5 receptor gene. In addition, a previously described polymorphism in the ®rst intron of the NPY Y1 receptor gene was analysed. RESULTS: The coding region of the NPY Y5 receptor gene encompasses one exon. A single mutation, which results in a non-conservative amino acid substitution in the ®rst extracellular domain of the receptor (Glu-4-Ala), and one silent polymorphism (Gly-426-Gly-Gly) at nucleotide position 1278 (G?A) were detected by TGGE. Both tests for association and linkage to the NPY Y1 and NPY Y5 receptor polymorphisms were negative among all cohorts. The Glu-4-Ala mutation was found only in a single patient with AN and her mother. CONCLUSION: The results do not support a major role of the NPY Y5 receptor gene in the variability of body weight in children and adolescents.
Introduction
The neuropeptide Y (NPY) is one of the most abundant neuropeptides in the brain and modulates numerous physiological processes including control of energy balance, blood pressure and circadian rhythm.
1,2 These effects are mediated by several distinct NPY receptors. Up to now, six human NPY Y receptors have been cloned. 3±10 Five of these are functional G-coupled receptors, one is a pseudogene. 9, 10 NPY is a potent stimulant of food intake after administration into the paraventricular nucleus. 11 It is predominantly expressed in the arcuate nucleus and lateral hypothalamus, regions known to play a role in the central regulation of feeding behaviour. Aberrations in the NPY signalling pathway are predicted to result in hypertension, eating disorders and anxiety. 12 Increased levels of NPY are found in the cerebrospinal¯uid of patients with Anorexia Nervosa (AN) or bulimia nervosa 13 and in the hypothalamus of obese rodents. 14, 15 Interestingly, knock out mice for NPY were shown to have normal feeding behaviour. 16 However, in obaob mice de®cient for NPY (NPY 7a7 obaob mice) the obesity syndrome is attenuated, thus implicating NPY-containing neural pathways as mediators of hyperphagia, hypometabolism and endocrine alterations resulting from chronic leptin de®ciency. 17 The NPY Y5 receptor in rats is assumed to play a major role in NPY induced food intake. 7, 8 The NPY Y5 receptor mRNA is expressed in brain regions known to be involved in the central regulation of feeding behaviour, such as the lateral hypothalamus, the paraventricular nucleus and the arcuate nucleus. 7 Furthermore, the pharmacological pro®le differs from the other members of the NPY Y receptor family. Intracerebroventricular administration of a weak Y5 receptor-selective agonist (human (D-Trp32)NPY) produces a statistically signi®cant increase in food intake in vivo in rats. 7 It is unlikely that the NPY Y1 receptors mediate NPY induced feeding, because these receptors are sparse in those areas of the hypothalamus which are most sensitive to the hyperphagic action of NPY. 18 Additionally, human pancreatic polypeptide (PP) and human peptide YY (PYY)3-36, two robust stimulants of feeding in vivo are weak or inactive agonists of the NPY Y1 receptors in vitro. 7 The roles of NPY and its receptors in human energy homeostasis are unknown.
The human Y5 and Y1 receptor genes are transcribed in opposite directions from a common promoter region on chromosome 4q31. 3-32. 7,8,19 A common restriction site polymorphism has been described in the ®rst intron of the NPY Y1 receptor gene, approximately 21 kb upstream of the Y5 receptor gene. 3, 7, 19 Herzog et al 20 2 ) subjects. They found no association between this polymorphism and obesity. Co Ãte Â et al 21 analysed this polymorphism in 276 individuals, in relationship to energy intake and body composition phenotypes. They found that the less frequent receptor variant is weakly associated with parameters related to energy intake. The polymorphism is not associated with BMI and body composition measures, according to Co Ãte Â et al.
21
Here we screened the coding region of the NPY Y5 receptor gene for mutations by temperature gradient gel electrophoresis (TGGE) in cohorts belonging to different weight extremes. TGGE is able to detect mutations in PCR-fragments of up to 550 bp 22±24 with a high sensitivity, especially if a GC-clamp is added to one of the primers. 25 We hypothesised that the biallelic Pstl polymorphism in the ®rst intron of the NPY Y1 receptor gene is in linkage disequilibrium with a putative mutation in the promoter or coding region of the NPY Y5 receptor gene or with mutations in the NPY Y1 receptor gene. Therefore, the Pstl polymorphism was also screened.
Materials and methods

Study cohorts
Study cohorts ( ) were analysed.
Study cohorts for transmission disequilibrium tests
For studies of linkage and linkage disequilibrium, both parents of 155 obese index probands and both parents of 57 patients with AN were analysed.
Study cohorts for mutation screening
Cohorts belonging to different weight extremes were screened by TGGE for mutations in the coding region of the NPY Y5 receptor gene. The likelihood of ®nding a mutation or polymorphism in this gene was increased by use of study cohorts differing in regard to body weight (87 extremely obese children and adolescents: BMI, 26 , aged, 11±21 y.
Statistical methods
Quantitative differences for the genotypes of the NPY Y1 and Y5 receptor polymorphisms between extremely obese children and adolescents or patients with AN and underweight students, were investigated by the two-sided exact test of Fisher for comparison of allele frequencies. To check for linkage and linkage disequilibrium jointly, the transmission disequilibrium test (TDT) 32 was applied to 155 obese probands, 57 patients with AN and both of their parents, respectively. Due to the exploratory design of our study, we did not formulate speci®c hypotheses a priori. Therefore, we report test-speci®c nominal P values.
DNA-Isolation
EDTA anticoagulated venous blood samples were collected from the aforementioned individuals. Leukocyte DNA was isolated by the salting out procedure according to a modi®ed protocol of Miller et al. 33 
Sequencing
Oligonucleotide primers were chosen according to the human cDNA NPY Y5 receptor sequence published by Gerald et al. 7 and Hu et al. 8 To determine the genomic organisation of the NPY Y5 receptor gene PCR-products from primerset A±E (see Table 2 ) were used to amplify the entire coding region. The PCR was performed with genomic DNA in a reaction mixture of 50 ml (Table 2 ). Samples were processed in a GeneAmp PCR System 9600 (Perkin Elmer, Weiterstadt, Germany). The ampli®cation products were gel puri®ed by QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Automated sequencing of PCR products was performed with¯uorescently labelled dideoxyterminators using the PRISM Ready Reaction Kit (Applied BiosystemsaPerkin Elmer). 4 pmol of either the forward or reverse primers of the primersets were used for sequencing. The cycle sequencing products were run on an ABI 373 DNASequencer (48 cm long; 6% Long ranger gel solution (Serva, Heidelberg, Germany), 8 M urea; 1 6 TBE (89 mM Tris-HCl, 89 mM boric acid, 2.5 mM EDTA (Applied BiosystemsaPerkin Elmer)) for 18 h at 38 W. Primersets A and E were used for sequencing of the TGGE variants.
Screening for mutations
For TGGE, PCR-products (Table 3) were obtained by Primersets F±K mainly as described above. Duration of all cycling steps was prolonged. The melting behaviour of a given DNA-fragment was calculated by use of the programs POLAND and MIS-MATCH. 22 It was possible to predict a gel shift for a potential mutation at every position of the analysed DNA fragments. 22 Primers were chosen according to the analysis of the melting behaviour, to allow for detection of all putative mutations. The optimal temperature ranges were determined by perpendicular TGGE and were carried out with 150 ml sequenced wild-type DNA. The sample was applied to a 6% polyacrylamide (PAA; Pharmacia, Freiburg, Germany) gel (210 6 210 6 0.5 mm, 8 M urea, 20 mM MOPS, 1 mM EDTA pH 8.0). The electrophoresis started at 20 C with 260 V for 30 min. After establishing the temperature gradient (cathode: T1 40 C and anode: T2 70 C) the electrophoresis was performed for 2 h at 260 V. The optimal temperature range was determined and used for parallel TGGE. 4 ml ampli®-cation product (3 ml sample mixed with 1 ml wild-type probe in order to detect homozygous mutations carriers) was applied to the gel (6±7% PAA). After 20 min pre-electrophoresis at 20 C, the temperature gradient was established (Table 3 ) and the gel was run for 1.5±2 h at 260 V. Bands were visualised by silverstaining. 34 Screening the NPY Y5 receptor gene for the detected mutation and polymorphism
To allow rapid genotyping, PCR-based RFLP-and allele speci®c ampli®cation-assays were developed.
PCR-RFLP for the A?C transversion at nucleotide position 11 (Glu-4-Ala) was performed with primerset A (Table 2 ). 15 ml of the PCR-product were digested with Hin6I (Eurogentec, Seraing, Belgium). The undigested wild-type allele had a fragment length of 271 bp, the mutation was cleaved by Hin6I and produced fragments of 65 bp and 206 bp in length. TTA ATC CCA TTA TTA AGA ATT (to detect the wild-type and mutated sequence, respectively). Both ampli®cations were performed in a total volume of 50 ml. Sequencing was performed in some cases to check that the sequence-speci®c primers detected the correct alleles.
Screening of the NPY Y1 receptor gene polymorphism
We genotyped all the above cohorts for the two alleles of the NPY Y1 receptor gene. 3 Ampli®cation was performed in a total volume of 25 ml. Primer sequences were received as personal communication from Prof Dr Herzog (Garvan Institute of Medical Research, Australia). 11 ml of the PCR-product were digested with PstI (Eurogentec, Seraing, Belgium). Digests were visualised on ethidium bromide stained agarose gels. Discrimination of the two alleles was performed as described by Herzog et al. 20 
Results
Sequencing of the coding region
Sequencing analysis of four normal weight individuals showed that the coding region of the NPY Y5 receptor gene consists of one exon with no intervening intron sequences.
Mutation screening
Mutation screening with TGGE revealed two bandshifts indicating DNA sequence variations in two positions of the gene. One of the variations was found by use of both short (316 bp; primerset F; Table 3 ) and large PCR fragments (584 bp, primerset G; Table 3 ), that ampli®ed DNA sequences coding for the N-terminus of the receptor gene. Sequencing analysis showed (Figure 1a) an A?C transversion at nucleotide position 11, leading to a non-conservative substitution of glutamic acid with alanine at aminoacid position 4 (Glu-4-Ala) of the N-terminal extracellular domain of the receptor.
The second bandshift was found by TGGE using a PCR fragment that spans from the 3rd intracellular domain to the C-terminus of the receptor (primerset K; Table 3 ). Sequencing revealed a G?A substitution at nucleotide position 1278 (Figure 2 ), which does not lead to an amino acid exchange (Gly-426-Gly).
The Glu-4-Ala variant was found in one patient with AN. The variation creates a Hin6I restriction site. A PCR-based restriction fragment length polymorph- ism (PCR-RFLP) was established to screen for mutation carriers (Figure 1b ) in the whole study cohorts (160 obese individuals, 128 underweight subjects and 58 patients with AN). Only the patient with AN and her unaffected mother were carriers of the Glu-4-Ala substitution. The allele frequency of the variant was estimated to be well below 1%. The Gly-426-Gly variant neither creates nor abolishes a restriction site, thus we discriminated the alleles by PCR with sequence-speci®c primers. The allele frequencies of the variant ranged from 0.11± 0.14 among the different cohorts (Table 4) . Homozygotes for the A-allele were not found. The allele frequencies did not differ signi®cantly between the extremely obese children and adolescents and the underweight students (P 0.89) or patients with AN and underweight students (P 0.38), respectively. The TDT for 155 trios each formed by an obese proband and both parents, revealed that 76 parents were heterozygous for the Gly-426-Gly polymorphism. Among these the G-allele was transmitted 35 times, whereas the A-allele was transmitted 41 times (P 0.49). Among the 33 heterozygous parents of 57 trios ascertained via the index proband with AN, the G-allele was transmitted 16 times (P 1.0). Hence, evidence for transmission disequilibrium of the G or A allele in obesity or in AN could not be found.
The allele frequencies (Table 4 ) of the PstI polymorphism of the NPY Y1 receptor gene are similar to frequencies formerly described. 20 No signi®cant differences between the allele frequencies were determined between the extremely obese children and adolescents and the underweight students (P 0.80) or patients with AN and underweight students (P 0.09), respectively. The TDT revealed that 138 parents of the obese cohort were heterozygous for the PstI-polymorphism, among these the y-allele was transmitted 77 times (P 0.17). Among the 50 heterozygous parents ascertained via the index proband with AN the y-allele was transmitted 22 times (P 0.40). Thus, none of the cohorts showed linkage or linkage disequilibrium between one of the alleles and obesity or AN.
Discussion
Two sequence variations (Glu-4-Ala, silent Gly-426-Gly) in the coding region of the NPY Y5 receptor gene were found. To our knowledge these are the ®rst genetic variations which have been identi®ed for a coding region of a human NPY receptor gene. The Glu-4-Ala mutation is rare (`1%) and was detected in a single index proband with AN. The allele was transmitted from the mother who showed no history of an eating disorder as assessed upon use of a psychiatric interview. A paternal cousin of the patient also had AN. These observations make it appear unlikely that the described variant plays a signi®cant role in the genetic predisposition to AN.
The silent polymorphism (Gly-426-Gly) was not more frequent in any of the cohorts analysed in this study. Neither this silent polymorphism, nor the NPY Y1 receptor polymorphism seems to be in linkage or linkage disequilibrium with obesity or AN. Our results are consistent with the aforementioned studies in that no evidence for association or linkage was found, even though our large study cohorts encompassed individuals with extreme obesity.
We are con®dent that we detected all mutations in the coding region of the NPY Y5 receptor gene in the analysed probands. The Glu-4-Ala mutation was detectable in a fragment of 584 bp, which underscores the fact that large PCR-fragments can be ef®ciently screened by TGGE. The PCR primers were chosen with the MISMATCH program 22 to ensure that all possible mutations are detected with TGGE. Hence, we were able to exclude a variant (Leu-63-Pro) found in rats 8 in the probands of our cohorts.
Conclusion
We conclude that in humans neither the NPY Y1 nor the NPY Y5 receptor genes have a major effect on the development of extreme obesity in children and adolescents or the development of AN. The coding region of the NPY Y5 receptor gene encompasses a single exon.
Note added in Proof Roche et al (1997) have recently also shown that alleles of markers in the chromosomal region of the NPY Y5 receptor gene are not linked to obesity.
